单克隆免疫球蛋白沉积的增殖性肾小球肾炎轻链型与可检测致病浆细胞克隆的高检出率相关
本文首次报道17例仅沉积单克隆免疫球蛋白轻链的增殖性肾小球肾炎(PGNMID-轻链)多中心队列,患者表现为肾炎或肾病综合征,88%可检测到骨髓浆细胞克隆。
要点
- PGNMID-轻链型患者中可检测到致病浆细胞克隆的比例高达88%。
- 肾脏反应依赖于血液学反应,浆细胞导向化疗可能改善肾脏预后。
- 单克隆轻链可能通过激活补体替代途径参与发病。
核心结论
- PGNMID-轻链型与PGNMID-IgG不同,其可检测到的致病浆细胞克隆频率更高。
- 正确识别该变异型至关重要,因为抗骨髓瘤药物可能改善肾脏预后。
研究设计与样本
- 多中心队列研究,纳入17例PGNMID-轻链型患者。
主要发现
- 17例患者中71%有单克隆丙种球蛋白肾病意义(MGRS),29%有多发性骨髓瘤。
- 血清和尿免疫固定电泳分别检出单克隆免疫球蛋白65%和73%,血清游离轻链异常83%,骨髓浆细胞克隆可检测88%。
- 肾活检多数呈膜增生性模式,免疫荧光显示沉积限于肾小球,轻链限制性(kappa占71%)伴C3沉积。
- 4例kappa型PGNMID-轻链的蛋白质组学分析显示kappa恒定区和可变区谱,无Ig重链证据;3例检测到补体替代途径和终末复合物蛋白谱,3例未检测到经典途径。
临床怎么用
- 对PGNMID-轻链型患者应积极检测致病浆细胞克隆,并考虑浆细胞导向化疗以改善肾脏预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IgG (mainly IgG3) is the most commonly involved isotype in proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID). Here we describe the first series of PGNMID with deposition of monoclonal immunoglobulin light chain only (PGNMID-light chain). This multicenter cohort of 17 patients presented with nephritic or nephrotic syndrome with underlying hematologic conditions of monoclonal gammopathy of renal significance (71%) or multiple myeloma (29%). Monoclonal immunoglobulin was identified by serum and urine immunofixation in 65% and 73%, respectively, with abnormal serum free light chain in 83%, and a detectable bone marrow plasma cell clone in 88% of patients. Renal biopsy showed a membranoproliferative pattern in most patients. By immunofluorescence, deposits were restricted to glomeruli and composed of restricted light chain (kappa in 71%) and C3, with granular appearance and subendothelial, mesangial and subepithelial distribution by electron microscopy. Proteomic analysis in four cases of kappa PGNMID-light chain revealed spectra for kappa constant and variable domains, without evidence of Ig heavy chains; spectra for proteins of the alternative pathway of complement and terminal complex were detected in three. The classical pathway was not detected in three cases. After median follow up of 70 months, the renal response was dependent on a hematologic response and occurred in six of ten patients treated with plasma cell-directed chemotherapy but none of five patients receiving other therapies. Thus, PGNMID-light chain differs from PGNMID-IgG by higher frequency of a detectable pathogenic plasma cell clone. Hence, proper recognition is crucial as anti-myeloma agents may improve renal prognosis. Activation of an alternative pathway of complement by monoclonal immunoglobulin light chain likely plays a role in its pathogenesis.
引用
- Nasr SH, Larsen CP, Sirac C, et al. Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone. Kidney Int. 2019. PMID: 32001067. doi:10.1016/j.kint.2019.10.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。